Recent developments include Q2 2026 earnings results and earnings call highlights, with the stock reaching 52-week highs amid positive sector trends. Prior quarters' earnings call transcripts provide additional operational insights.

• Anika Therapeutics reported Q2 2026 earnings with basic EPS of $0.25 and diluted EPS of $0.24 [S2].
• The company’s stock reached 52-week highs alongside other biotech stocks following Q2 results [N1].
• Q2 2026 earnings call highlighted operational performance and ongoing investments in R&D and manufacturing capacity [N2].
• Q1 2026 and Q2 2025 earnings call transcripts provide context on company strategy and financial results [N3][N4].

Anika Therapeutics benefits from exclusive manufacturing agreements with a leading medical technology company, providing a stable revenue base. The company's focus on HA-based products for orthopedic applications aligns with ongoing demand in the medical field. Investments in manufacturing capacity and R&D for new products like Cingal and Integrity may enhance its product portfolio. Strong liquidity and cash flow from operations support operational flexibility. The company's revenue recognition practices and diversified sales channels provide clarity and consistency in financial reporting.

The company faces significant customer concentration risk, with 50% of revenue from a single customer, which could impact revenue stability if purchasing patterns change. Operating losses and net losses in recent years highlight challenges in profitability. The divestiture of certain asset groups and related notes receivable introduce some uncertainty in cash flow. Market competition and regulatory risks inherent in medical technology could affect product acceptance and sales. The company's reliance on a limited product portfolio and the need for continued R&D investment present execution risks.

Anika Therapeutics' moat is supported by its proprietary manufacturing processes for HA-based orthopedic products and exclusive long-term supply agreements with major partners such as J&J MedTech. The company's products, including Orthovisc and Monovisc, benefit from established market presence and regulatory approvals. The exclusivity of manufacturing rights and the proprietary nature of the products create barriers to entry for competitors. Additionally, the company's diversified sales channels and ongoing investments in R&D contribute to sustaining its competitive position. However, customer concentration risk remains a factor, with significant revenue dependence on a few large customers.

• Customer Concentration Risk: A significant portion of revenue is derived from a small number of large customers, especially J&J MedTech, which accounted for 50% of revenue in 2025. Changes in purchasing behavior or contract terms by these customers could materially impact the company's financial results.
• Profitability Challenges: The company has reported operating and net losses in recent years, reflecting challenges in managing costs and achieving sustainable profitability.
• Dependence on Key Products and Partners: Revenue is heavily dependent on products like Orthovisc and Monovisc and exclusive agreements with partners such as J&J MedTech, which may limit diversification and increase risk if these relationships change.
• Regulatory and Market Risks: As a medical technology company, Anika faces risks related to regulatory approvals, product acceptance, and competition, which could affect sales and growth.
• Liquidity and Capital Needs: While liquidity ratios are strong, ongoing investments in R&D and manufacturing capacity require cash, and the company relies on operating cash flow and credit facilities to meet these needs.

• Anika Therapeutics, Inc. operates in one business segment focused on the development, manufacturing, and sale of products primarily related to hyaluronic acid (HA)-based technology for orthopedic and other medical applications [S1].
• The company generates revenue principally through three customer types: commercial partnerships, hospitals and ambulatory surgical centers (ASCs), and distributors [S1].
• Commercial partnership sales involve direct sales to partners who handle downstream sales and marketing; these agreements may include licenses, development services, and product supply, with revenue recognized upon shipment [S1].
• Sales-based royalties and milestones are recognized when the underlying sales occur or performance obligations are satisfied, typically in the same period as partner sales [S1].
• J&J MedTech is the company's largest customer, accounting for 50% of total revenues for the year ended December 31, 2025, down from 57% the prior year [S1].
• The collaboration with J&J MedTech includes contracts for Orthovisc and Monovisc products, with Anika as exclusive manufacturer and J&J MedTech responsible for marketing and distribution [S1].
• Long-term contracts with OEM partners do not allow other product source suppliers, and manufacturing is proprietary and not easily replicated [S1].
• Sales to hospitals and ASCs often involve consigned inventory, with revenue recognized upon surgical implantation of the product [S1].
• Distributor sales, mainly outside the U.S., involve shipment to distributors who resell to sub-distributors and healthcare providers; revenue is recognized upon shipment to the distributor [S1].
• The company has no significant deferred revenue as of December 31, 2025 and 2024 [S1].
• Payment terms are consistent with market practice, generally within one year, and the company does not have material financing components in contracts [S1].
• The company maintains product warranties limited to assurance that products meet contractual specifications and holds product liability insurance; historical warranty claims have been immaterial [S1].
• For the year ended December 31, 2025, revenue was $112.8 million, down from $119.9 million in 2024 [S1].
• Gross profit was $63.8 million in 2025, down from $76.0 million in 2024 [S1].
• Operating expenses totaled $74.9 million in 2025, including $25.8 million in R&D and $49.1 million in SG&A, down from $81.1 million in 2024 [S1].
• Loss from operations was $11.1 million in 2025, compared to a loss of $5.1 million in 2024 [S1].
• Net loss was $10.9 million in 2025, compared to a net loss of $56.4 million in 2024, which included a $47.6 million loss from discontinued operations [S1].
• Basic and diluted EPS for Q2 2026 were $0.25 and $0.24 respectively [S2].
• As of June 30, 2026, cash and cash equivalents were $38.4 million, with short-term investments of $25.8 million as of March 31, 2026 [S2].
• Current assets as of June 30, 2026 were $99.2 million, with current liabilities of $22.1 million, resulting in a current ratio of 4.48 and a cash ratio of 2.9 [S2].
• The company has a revolving credit facility with Bank of America providing up to $75 million, with no borrowings outstanding as of December 31, 2025 [S1].
• Cash provided by operating activities was $11.2 million for 2025, up from $5.4 million in 2024 [S1].
• Cash used in investing activities was $0.4 million in 2025, down from $8.3 million in 2024, reflecting proceeds from asset sales and increased capital expenditures for manufacturing capacity expansion [S1].
• Cash used in financing activities was $10.6 million in 2025, down from $12.7 million in 2024, primarily due to reduced stock repurchases [S1].
• The company faces customer concentration risk, with a small number of large customers, especially J&J MedTech, accounting for a significant portion of revenue; changes in these customers' purchasing could materially impact the business [S1].
• The company is investing in research and development for new products and clinical trials related to its HA-based technology, including products named Cingal and Integrity [S1].
• The company has divested certain asset groups (Arthrosurface and Parcus Medical) and holds notes receivable related to these divestitures, with repayment dependent on cash receipts from the divested entities [S1].
• The company recognizes revenue in accordance with ASC 606, applying a five-step model to identify performance obligations and recognize revenue when control transfers to customers [S1].
• The company’s supply agreements generally do not provide material rights to customers that would require separate revenue recognition [S1].
• The company’s payment terms and revenue recognition practices are consistent with industry standards and do not involve significant financing components [S1].
• The company’s product warranty does not create separate performance obligations and is limited to assurance that products meet contractual specifications [S1].
• The company’s financial statements are prepared in accordance with U.S. GAAP and audited by an independent registered public accounting firm [S1].
• The company’s operating segment is managed on a consolidated basis, with the President and CEO as the chief operating decision maker [S1].
• Recent news highlights include Q2 2026 earnings call and results, with the stock reaching 52-week highs amid broader biotech sector strength [N1][N2].
• Q1 2026 earnings transcript and Q2 2025 earnings call transcript provide additional operational insights [N3][N4].
• The company’s liquidity position as of mid-2026 shows strong current and cash ratios, supported by cash, short-term investments, and credit facility availability [S2].